SCHEMBL6530784

SCHEMBL6530784

O=c1[nH]c2ncc(Br)cc2c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.57
AURKA O14965 6/20 0.57
AURKB Q96GD4 3/20 0.45
JAK2 O60674 2/20 0.45
PRKD3 O94806 2/20 0.45
MAP4K4 O95819 2/20 0.45
FGFR1 P11362 2/20 0.45
FLT1 P17948 2/20 0.45
KDR P35968 2/20 0.45
CLK2 P49760 2/20 0.45
CDK5 Q00535 2/20 0.45
MAP4K2 Q12851 2/20 0.45
DYRK1A Q13627 2/20 0.45
TAOK1 Q7L7X3 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
PLK4 O00444 1/20 0.45
ROCK2 O75116 1/20 0.45
PRKCG P05129 1/20 0.45
INSR P06213 1/20 0.45
CDK1 P06493 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6529886 0.81 PGR (0.42) PARP1AURKAAURKBJAK2PRKD3
SCHEMBL6521528 0.80 PARP1 (0.60) PARP1AURKAAURKBTNKSPARP15
SCHEMBL3454670 0.80 PARP1 (0.57) PARP1AURKAAURKBJAK2ROCK1
SCHEMBL15318812 0.79 CHEK1 (0.54) AURKAAURKBJAK2PRKD3MAP4K4
SCHEMBL1253533 0.77 KDR (0.62) AURKAAURKBJAK2PRKD3MAP4K4
SCHEMBL6525764 0.76 PARP1 (0.54) PARP1AURKAAURKBFGFR1FLT4
SCHEMBL6522107 0.76 AURKA (0.54) PARP1AURKAAURKBFGFR1FLT4
SCHEMBL6531057 0.73 PARP1 (1.00) PARP1AURKAAURKBFGFR1FLT1
SCHEMBL3455188 0.72 IP6K1 (0.54) PARP1AURKAPDGFRBPDGFRABRD4
SCHEMBL20240684 0.72 ADORA2A (0.62) AURKAAURKBJAK2PRKD3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 PARP1 1693/4885AURKA 538/4885AURKB 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.